A new drug targeting the PI3K gene in patients with advanced breast cancer shows promising results in an early phase I investigational study conducted at Virginia G. Piper Cancer at Scottsdale Healthcare, according to a presentation by oncologist Dr. Daniel D. Von Hoff at the 47th annual meeting of the American Society of Clinical Oncology (ASCO).
The drug under investigation, GDC-0941, manufactured by Genentech Inc., South San Francisco, Calif., targets the PI3K gene, which is abnormal in about 20-30 percent of patients with advanced breast cancer.
In collaboration with the Karmanos Cancer Institute in Detroit, Mich. and the Dana-Farber Cancer Institute in Boston, Mass., Dr. Von Hoff and his team at Virginia G. Piper Cancer Center Clinical Trials initially tested the drug in 97 patients with various advanced cancers. Patients experienced manageable side effects including diarrhea, nausea, taste alteration, rash, fatigue, itchiness, vomiting and decreased appetite.
The study resulted in significant shrinkage of tumors in two patients - one with advanced cervical cancer and one with advanced breast cancer. Another patient with ampullary cancer of the pancreas is currently on the study with stable disease for more than a year.
Dr. Von Hoff is Physician-In-Chief and Distinguished Professor at the Translational Genomics Research Institute (TGen), Chief Scientific Officer at Scottsdale Healthcare and US Oncology. Virginia G. Piper Cancer Center Clinical Trials is a partnership between TGen and Scottsdale Healthcare that treats cancer patients with promising new drugs through clinical trials at the Virginia G. Piper Cancer Center in Scottsdale, Ariz.
"We are very excited about personalizing therapy for breast cancer and gynecologic cancer patients with PI3K inhibitors," said Dr. Von Hoff, who made his presentation in June during ASCO's annual meeting in Chicago. "The next step will be to test samples from breast cancer patients for PI3K mutations and treat those patients accordingly."
Breast cancer remains one of the deadliest cancers among women, with approximately 180,000 new cases each year.
ASCO is the country's largest cancer research conference, with attendance exceeding 35,000 oncology professionals from around the world.
The Virginia G. Piper Cancer Center at Scottsdale Healthcare opened in 2001 as the first comprehensive cancer center in greater Phoenix, offering comprehensive cancer care and research through Phase I clinical trials, diagnosis, treatment, prevention and support services in collaboration with leading researchers and community oncologists. The Scottsdale Healthcare cancer program holds Accreditation with Commendation from the Commission on Cancer of the American College of Surgeons.
Research at the Virginia G. Piper Cancer Center at Scottsdale Healthcare is conducted in collaboration with the Translational Genomics Research Institute (TGen) and the Scottsdale Healthcare Research Institute.
Individuals seeking information about eligibility to participate in clinical trials at the Virginia G. Piper Cancer Center at Scottsdale Healthcare may contact the cancer care coordinator at 480-323-1339; toll free at 1-877-273-3713 or via email at firstname.lastname@example.org.
Scottsdale Healthcare is the community-based, nonprofit parent organization of the Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale Healthcare Research Institute, Scottsdale Healthcare Osborn Medical Center, Scottsdale Healthcare Shea Medical Center, Scottsdale Healthcare Thompson Peak Hospital and Scottsdale Healthcare Foundation. For more information, visit www.shc.org.
About the Virginia G. Piper Cancer Center at Scottsdale Healthcare
The Virginia G. Piper Cancer Center at Scottsdale Healthcare in Scottsdale, Ariz. offers comprehensive cancer care and research through Phase I clinical trials, diagnosis, treatment, prevention and support services in collaboration with leading scientific researchers and community oncologists. Scottsdale Healthcare is the nonprofit parent organization of the Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale Healthcare Research Institute, Scottsdale Healthcare Osborn Medical Center, Scottsdale Healthcare Shea Medical Center and Scottsdale Healthcare Thompson Peak Hospital. For more information, visit www.shc.org.Press Contact:
Steve Yozwiak | EurekAlert!
Cryo-electron microscopy achieves unprecedented resolution using new computational methods
24.03.2017 | DOE/Lawrence Berkeley National Laboratory
How cheetahs stay fit and healthy
24.03.2017 | Forschungsverbund Berlin e.V.
Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.
The results will be published on March 22 in the journal „Astronomy & Astrophysics“.
Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...
Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.
Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...
In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...
20.03.2017 | Event News
14.03.2017 | Event News
07.03.2017 | Event News
24.03.2017 | Materials Sciences
24.03.2017 | Physics and Astronomy
24.03.2017 | Physics and Astronomy